CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Express News | Y-mAbs Therapeutics Shares Are Trading. The Stock May Be Rebounding After Falling Earlier in the Week on Weak Earnings and Guidance
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
Y-mAbs Therapeutics Is Maintained at Underweight by Morgan Stanley
A Quick Look at Today's Ratings for Y-mAbs Therapeutics(YMAB.US), With a Forecast Between $21 to $26
Express News | Y-mAbs Therapeutics Inc. : Morgan Stanley Cuts Target Price to $11.00 From $12.00
Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders
